// STATE LEGISLATION TRACKER

Hawaii SB 1613: RELATING TO CANNABIS.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Introduced

State: Hawaii
Bill: SB 1613
Session: 2026
Filed: 2025-01-23
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Hawaii SB1613 is a cannabis bill focused on adult-use cannabis, hemp, and creation or funding of cannabis-related state oversight. Based on the title, subjects, and introduced status provided, it does not appear to regulate compounded peptides, off-label prescribing, telehealth prescribing, NP or naturopathic scope, FDA 503A/503B compounding, controlled substances scheduling for peptides, or prescription monitoring.

Key Points

No apparent change to peptide prescribing or access
No apparent change to compounding pharmacy rules
No apparent change to telehealth peptide care
No apparent change to NP or naturopathic scope
Applies to cannabis and hemp, not peptide therapies

What to Watch For

Note Watch for amendments that add broader drug-control, dispensing, or licensing language.

Note Cannabis oversight changes may affect clinics offering cannabis care, but not peptide care directly.

Concern If later versions expand prescription monitoring or controlled-substance rules, peptide-adjacent clinics should recheck impact.

Where the Bill Stands

The bill has been introduced, so it is early in the legislative process and may change if amended.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws